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Background: There is still little data about long term results of unprotected left main
stenting. In a multicenter randomized trial we compared percutaneous coronary
intervention (PCI) using Sirolimus eluting stents to bypass revascularisation (CABG)
for patients with significant left main stenosis. We present the cumulative 5-years
results and therefore the longest available results of a randomized left main study at
all.
Methods: Between 8/2003 and 9/2008 a total of 201 pts with hemodynamically
significant stenosis of the unprotected left main coronary artery were recruited in 4
german centers. The primary endpoint of the study was death, myocardial infarction,
stroke and target vessel re-intervention. Hundred patients were randomized within the
PCI-group and 101 patients within the CABG-group. There were no differences in the
baseline characteristics. The left main lesion was located at the ostium in 22%, midshaft
in 8% and at the bifurcation in 70%. Nearly half of the CABG patients were operated
on using an off-pump technique (46%) and with total arterial revascularization in 65%.
Complete revascularization was achieved in both groups.
Results: Over a cumulative period of 5 years, 14 pts (14.1%) within the CABG group
and 11 pts (11.1%) within the PCI group died. Myocardial infarction occurred in 2
patients after CABG and in 4 PCI patients after PCI. One patient had a stroke in the
PCI group and 2 patients in the CABG group. The incidence of stroke was found to be
low (1 vs 2 within the PCI and CABG group, respectively). Reintervention within the
PCI group was required in 20 patients (3/20 underwent CABG) vs 9 patients within
the CABG goup. Cumulative MACCE rate after 5 years was 36.4% for the PCI group
vs 27.3% for the CABG group (p = 0.16 for non-inferiority).
Conclusion: In patients with unprotected left main stenosis, mortality during a 5-year
follow-up was found is low. There were no significant differences in the primary
endpoints death, myocardial infarction and stroke between the 2 treatments groups.
However, for overall MACCE rate, non-inferiority for PCI could not be demonstrated.
This was a result of a higher rates of target vessel re-intervention within the PCI group
during follow-up
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Long-term outcome after percutaneous coronary intervention with titanium-
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infarction: a five-year follow-up of the TITAX-AMI trial
Petri Olavi Tuomainen1, Antti Ylitalo2, Matti Niemelä3, Mikko Pietilä4, Jussi Sia5,
Kai Nyman6, Juhani Airaksinen4, Pasi P Karjalainen2
1The Heart Center and The Department of Internal Medicine, Kuopio University
Hospital, Kuopio, Finland; 2Satakunta Central Hospital, Pori, Finland; 3Oulu
University Hospital, Oulu, Finland; 4Turku University Hospital, Turku, Finland;
5Kokkola Central Hospital, Kokkola, Finland; 6Jyväskylä Central Hospital,
Jyväskylä, Finland
Background: The aim of this study was to evaluate the long-term safety and efficacy
of the titanium-nitride-oxide-coated (TITANOX) stent and the paclitaxel-eluting stent
(PES) in patients with acute myocardial infarction (MI) treated with a percutaneous
coronary intervention (PCI).
Methods: Altogether 425 patients presenting with acute non-ST-elevation MI or ST-
elevation MI were randomly assigned to receive TITANOX stent or PES during PCI.
The primary end point was a composite of MI, target lesion revascularization (TLR)
or death from cardiac causes.
Results: At 12 months, there was no significant difference between patients receiving
TITANOX stent or PES in the rate of primary end point (10.3% vs. 12.8%, p=0.5),
whereas a significantly lower rate of primary end-point was observed in the TITANOX
stent group compared with the PES group (11.2% vs. 21.8%, p<0.01) after a two-year
follow-up. After three years the rates of MI (6.1% vs. 16.6%, p<0.01), cardiac death
(1.4% vs. 5.2%, p<0.05), MACE (13.1% vs. 23.7%, p<0.01) and definite stent
thrombosis (ST) (0.5% vs. 6.6%, p<0.001) were significantly lower in the TITANOX
arm compared with the PES arm. The five-year follow-up will be completed within a
few months and the results will be presented in TCT 2011 congress if accepted.
Conclusion: The implantation of a TITANOX stent had resulted in better clinical
outcome compared with a PES during both two and three years of follow-up among
patients treated for acute MI. The long-term outcome will be updated after a five-year
follow-up.
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Background: Bivalirudin use during primary percutaneous coronary intervention
(PCI) is nowadays a cornerstone for the management of ST elevation myocardial
infarction (STEMI). However, an increased acute stent thrombosis rate has been found
in patients treated with bivalirudin in the Horizons-AMI trial. A prolonged infusion
after PCI has already been shown to be a safe and effective tool in patients undergoing
complex urgent or elective PCI in the Probi Viri study. We examined the effects of a
prolonged drug infusion after primary PCI.
Methods: From the database of five high-volume italian centers, we compared a group
of patients treated with a 4-hour prolonged bivalirudin infusion after PCI with two
groups treated with a normal, peri-PCI infusion and heparin+abciximab for 12 hours.
Primary study endpoint was >70% ST segment resolution (STR) within 90 minutes
after PCI, secondary endpoints were partial (>50%) STR within 90 min and intra-
hospital TIMI major and minor bleedings.
Results: Study population consisted of 264 patients undergoing primary PCI, all pre-
treated with aspirin and clopidogrel (600 mg). The three study groups did not differ
significantly for baseline characteristics. Primary endpoint in prolonged bivalirudin,
normal bivalirudin and heparin+abciximab groups was achieved respectively in 69.8%,
48.8% and 69.6% of patients (p between prolonged and standard infusion = 0.048,
between prolonged infusion and abciximab =0.98). Major bleedings and other
secondary study endpoints were not significantly different between the study groups.
Conclusion: A strategy of prolonged bivalirudin infusion after primary PCI seems
equivalent to a strategy with heparin+abciximab and better than a standard infusion in
obtaining improved early microvascular reperfusion. Further studies with a bigger
population are needed to clarify if this strategy exerts clinical benefits.
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Background: Recent data suggests patients with coronary disease in large arteries are
at increased risk of adverse events after PCI with first-generation drug-eluting stents
(DES) as compared with bare-metal stents (BMS). We sought to investigate this
observation in patients undergoing Primary PCI.
Methods: 2447 consecutive patients undergoing Primary PCI for STEMI at a London
centre between Oct 2003 and May 2010 were included. The primary end point used
was major adverse cardiac events (MACE) defined as death, myocardial infarction
(MI), stroke and target vessel revascularization (TVR).
Results: Of the 2447 patients 933 required stents between 3 and 4mm in diameter, 809
were BMS and 124 DES. The DES group had higher rates of diabetes (22% vs 13% p
= 0.01), previous MI (20% vs 12%, p = 0.02) and previous PCI (10% vs 5%, p=<0.04).
There was a higher average number of stents used in the DES group (1.7 vs 1.5, p
=0.03) and a higher average stent length in the DES group (19.12 vs 16.05, p=0.002).
There was a significant difference in MACE between the two groups in favour of DES
(12% BMS v 5% DES group [p = 0.04) at 3 years (figure 1). The rate of target-vessel
revascularization was significantly reduced among patients receiving DES with TVR
rates of 2.2% among patients receiving DES compared to 8.1% among those receiving
BMS(p = 0.03). There were no significant differences in the rate of death, myocardial
infarction, or stent thrombosis.
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Figure 1. K-M curve showing outcome out to 3 years
Conclusion: In patients requiring stenting of large coronary arteries during primary
PCI, there was reduced MACE in patients treated with DES. This benefit was primarily
driven by decreased target vessel revascularisation.
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Background: Limited data are available on the predictors and implications of
gastrointestinal (GI) bleeding in ST-elevation Myocardial infarction (STEMI) patients,
whose contemporary management includes a combination of anticoagulation and
double or triple antiplatelet therapy. Therefore we assessed the predictors and
prognostic value for one year mortality of GI bleedings in STEMI patients.
Methods: We analyzed the occurrence of a GI bleeding within 1 year from the index
procedure, in 1762 consecutive STEMI patients undergoing pPCI between 1-1-2003
and 31-8-2008, in a large tertiary PCI center. Bleeding and bleeding source were
recorded from chart review. A GI bleeding was defined as an episode of hematemesis,
melena or red blood loss per rectum with a haemoglobin decrease ≥ 3 g/dL. Predictors
of GI bleeding were calculated using a stepwise logistic regression analysis. The
prognostic values of a GI bleeding for one-year mortality was calculated using a
stepwise Cox proportional Hazards models treating the development of a GI bleeding
as time-dependant covariate, including the following candidate covariables: age, sex,
history of diabetes, hypertension, hypercholesterolemia, current smoking, prior PCI,
prior CABG, previous MI, baseline creatinin clearance, baseline Hb, heart rate and
systolic blood pressure, shock, peak CK-MB release and multivessel disease.
Results: 39 (2.2%) patients suffered a GI bleeding within one year. Predictors of GI
bleeding were age (OR 1.07, 95% CI 1.04 – 1.11, p < 0.001), current smoker (OR 2.71,
95% CI 1.25 – 5.90, p = 0.012), previous CABG (OR 4.81, 95% CI 1.64 – 14.1, p =
0.004), shock (OR 2.59, 1.06 – 6.32, p = 0.037) and the use of GP IIb/IIIa inhibitor
(OR 2.58, 95% CI 1.27 – 5.24, p = 0.009). After adjustment for other predictors of one
year mortality in a time-dependant model, GI bleeding was associated with a
statistically significant higher risk for one year mortality: HR 2.69 (1.16 – 6.26, p =
0.019).
Conclusion: GI bleeding in the setting of STEMI is independently associated with
increased one-year mortality.
TCT-332
Four-Year Cardiovascular Event Rates Were Lower in Myocardial Infarction
Patients with Early Increases in Mobilization of Oct-4-high Nanog-high Stem
Cells
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Background: The aim of this study was to investigate the effects of early peripheral
mobilization of stem cells with pluripotency gene expression on cardiovascular events
in patients with ST-elevation myocardial infarction (STEMI) during the 4-year follow-
up.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated on days 0, 1
and 7 from patients with STEMI (n=40) and healthy controls (n=20). The numbers of
CD34+, CD117+, CD133+ and c-met+ stem cells were measured by flow-cytometry,
and PBMCs were analyzed by real-time PCR for Oct-4 and Nanog gene expressions.
The plasma concentrations of CRP, IL-6, SCF, SDF-1 and VEGF were measured with
ELISA kits. Major adverse cardiovascular events (MACEs) such as non-fatal MI,
death, stroke, target lesion revascularization were observed during the 4-year follow-
up.
Results: MACEs were significantly lower in patients with Oct-4 gene expression ≥
1.13 and Nanog gene expression ≥ 1.20 on admission (Table 1). The numbers of
CD34+, CD117+, CD133+ and c-met+ cells within 7 days after AMI did not show
significant differences in patients with or without MACE. Anti-inflammatory marker
such as IL-10 was significantly higher within 7 days after AMI in patients without
MACE. Inflammatory and angiogenic markers such as CRP, IL-6, SCF, SDF-1, and
VEGF did not show significant differences in patients with or without MACE.
Conclusion: mRNA levels of pluripotent embryonic stem markers such as Oct-4 and
Nanog were significantly higher in AMI patients without MACE during the 4-year
follow-up. Baseline Oct-4 and Nanog gene expression levels could be used as
predictors of MACE in STEMI patients.
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Background: Thromboaspiration (TA) during primary percutaneous intervention
(PPCI) is effective in opening the infarct-related artery in patients with ST-segment
elevation myocardial infarction (STEMI), leading to better reperfusion and improved
outcome. However, the effect of positive macroscopic efficiency of TA remains
unknown. We aimed to evaluate the impact of positive thrombus retrieval during PPCI
with manual TA on infarct size (IS), microvascular obstruction (MVO) and left
ventricular (LV) remodeling as assessed by contrast-enhanced magnetic resonance
imaging (CE-MRI) in a subset of patients with STEMI.
Methods: Inclusion criteria were patients aged <75 years, with STEMI referred for
PPCI within 12 hours of onset of symptoms, infarct-related artery ≥2.5 mm in diameter,
thrombus score ≥3 and no prior history of coronary disease. All patients underwent TA
before stenting and were categorized according to positive or negative TA. Clinical
and procedural characteristics of study population were recorded and CE-MRI was
performed at 5 days and 6-months to evaluate IS, MVO and LV remodeling as assessed
by LV volumes.
Results: 73 patients were enrolled, mean age 55±10 years; 39.7% in the positive TA
group. Main results are presented in the table. Clinical and procedural characteristics
(90-min total ischemic time, ST-segment resolution, post-procedural TIMI flow grade
and post-stenting myocardial blush grade, and peak troponin) did not differ
significantly between groups.
LVSVI = left ventricular stroke volume index
Conclusion: Positive thrombus retrieval during primary PPCI with manual TA in
STEMI reduces IS at 5 day and 6 months, reduces MVO and improves LV remodeling.
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